{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:43:14Z","timestamp":1784202194589,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12325-020-01329-7","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T18:03:21Z","timestamp":1588701801000},"page":"3463-3484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"37","author":[{"given":"Ona","family":"Kinduryte Schorling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Zwiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kaspers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hristo","family":"Iliev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"1329_CR1","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.clinthera.2016.09.001","volume":"38","author":"T Heise","year":"2016","unstructured":"Heise T, Jordan J, Wanner C, et al. Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38:2265\u201376.","journal-title":"Clin Ther"},{"key":"1329_CR2","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.clinthera.2016.08.008","volume":"38","author":"T Heise","year":"2016","unstructured":"Heise T, Jordan J, Wanner C, et al. Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. Clin Ther. 2016;38:2248\u201364.","journal-title":"Clin Ther"},{"key":"1329_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495\u2013502.","journal-title":"Nat Rev Endocrinol"},{"key":"1329_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0140-6736(18)32824-1","volume":"393","author":"S Verma","year":"2019","unstructured":"Verma S, Juni P, Mazer CD. Pump, pipes, and filter: do SGLT2 inhibitors cover it all? Lancet. 2019;393:3\u20135.","journal-title":"Lancet"},{"key":"1329_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139.","journal-title":"Lancet"},{"key":"1329_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes Vasc Dis Res. 2015;12:78\u201389.","journal-title":"Diabetes Vasc Dis Res"},{"key":"1329_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369\u201384.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1329_CR8","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.2337\/dc12-2673","volume":"36","author":"HU H\u00e4ring","year":"2013","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36:3396\u2013404.","journal-title":"Diabetes Care"},{"key":"1329_CR9","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"HU H\u00e4ring","year":"2014","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650\u20139.","journal-title":"Diabetes Care"},{"key":"1329_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/dom.12188","volume":"16","author":"CS Kovacs","year":"2014","unstructured":"Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147\u201358.","journal-title":"Diabetes Obes Metab"},{"key":"1329_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1329_CR12","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2337\/dc13-3055","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815\u201323.","journal-title":"Diabetes Care"},{"key":"1329_CR13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/dom.12503","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17:936\u201348.","journal-title":"Diabetes Obes Metab"},{"key":"1329_CR14","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420\u20138.","journal-title":"Diabetes Care"},{"key":"1329_CR15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u2013288.","journal-title":"N Engl J Med"},{"key":"1329_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"1329_CR17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1329_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1329_CR19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1329_CR20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.clinthera.2016.03.031","volume":"38","author":"S Kohler","year":"2016","unstructured":"Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38:1299\u2013313.","journal-title":"Clin Ther"},{"key":"1329_CR21","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","volume":"34","author":"S Kohler","year":"2017","unstructured":"Kohler S, Zeller C, Iliev H, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I\u2013III clinical trials. Adv Ther. 2017;34:1707\u201326.","journal-title":"Adv Ther"},{"key":"1329_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/dom.12081","volume":"15","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Seman L, Seewaldt-Becker E, et al. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:721\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1329_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/dom.12073","volume":"15","author":"T Heise","year":"2013","unstructured":"Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:613\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"1329_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12325-014-0126-8","volume":"31","author":"T Kadowaki","year":"2014","unstructured":"Kadowaki T, Haneda M, Inagaki N, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther. 2014;31:621\u201338.","journal-title":"Adv Ther"},{"key":"1329_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/jdi.12110","volume":"4","author":"S Kanada","year":"2013","unstructured":"Kanada S, Koiwai K, Taniguchi A, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4:613\u20137.","journal-title":"J Diabetes Investig"},{"key":"1329_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12933-014-0169-9","volume":"14","author":"R Nishimura","year":"2015","unstructured":"Nishimura R, Tanaka Y, Koiwai K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-h glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015;14:11.","journal-title":"Cardiovasc Diabetol"},{"key":"1329_CR27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/dom.12185","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154\u201360.","journal-title":"Diabetes Obes Metab"},{"key":"1329_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.diabres.2015.05.044","volume":"110","author":"HU H\u00e4ring","year":"2015","unstructured":"H\u00e4ring HU, Merker L, Christiansen AV, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;110:82\u201390.","journal-title":"Diabetes Res Clin Pract"},{"key":"1329_CR29","doi-asserted-by":"publisher","first-page":"1773\u201388:e1","DOI":"10.1016\/j.clinthera.2015.05.511","volume":"37","author":"CS Kovacs","year":"2015","unstructured":"Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37:1773\u201388:e1.","journal-title":"Clin Ther"},{"key":"1329_CR30","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/dme.12814","volume":"32","author":"L Merker","year":"2015","unstructured":"Merker L, H\u00e4ring HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with type 2 diabetes. Diabet Med. 2015;32:1555\u2013677.","journal-title":"Diabet Med"},{"key":"1329_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"M Roden","year":"2015","unstructured":"Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154.","journal-title":"Cardiovasc Diabetol"},{"key":"1329_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/dom.12469","volume":"17","author":"S Ross","year":"2015","unstructured":"Ross S, Thamer C, Cescutti J, et al. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2015;17:699\u2013702.","journal-title":"Diabetes Obes Metab"},{"key":"1329_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/03007995.2017.1405800","volume":"34","author":"KC Ferdinand","year":"2018","unstructured":"Ferdinand KC, Seman L, Salsali A. Design of a 24-week trial of empagliflozin once daily in hypertensive black\/African American patients with type 2 diabetes mellitus. Curr Med Res Opin. 2018;34:361\u20137.","journal-title":"Curr Med Res Opin"},{"key":"1329_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2337\/dc16-1347","volume":"40","author":"E S\u00f8fteland","year":"2017","unstructured":"S\u00f8fteland E, Meier JJ, Vangen B, et al. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care. 2017;40:201\u20139.","journal-title":"Diabetes Care"},{"key":"1329_CR35","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/dom.13352","volume":"20","author":"R Kawamori","year":"2018","unstructured":"Kawamori R, Haneda M, Suzaki K, et al. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2018;20:2200\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1329_CR36","doi-asserted-by":"crossref","unstructured":"Sone H, Kaneko T, Shiki K, et al. Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2019. (in press).","DOI":"10.1111\/dom.13909"},{"key":"1329_CR37","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Iliev H, Pfarr E, et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:e4\u2013e5.","journal-title":"Diabetes Care"},{"key":"1329_CR38","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial. Eur Heart J. 2016;37:1526\u201334.","journal-title":"Eur Heart J"},{"key":"1329_CR39","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.118.033810","volume":"138","author":"B Claggett","year":"2018","unstructured":"Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease. Circulation. 2018;138:1599\u2013601.","journal-title":"Circulation"},{"key":"1329_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","volume":"103","author":"S Geerlings","year":"2014","unstructured":"Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103:373\u201381.","journal-title":"Diabetes Res Clin Pract"},{"key":"1329_CR41","doi-asserted-by":"publisher","first-page":"e2886","DOI":"10.1002\/dmrr.2886","volume":"33","author":"H Qiu","year":"2017","unstructured":"Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017;33:e2886.","journal-title":"Diabetes Metab Res Rev"},{"key":"1329_CR42","unstructured":"US Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015. https:\/\/www.fda.gov\/media\/92185\/download. Accessed Sept 18, 2019."},{"key":"1329_CR43","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190\u20135.","journal-title":"Diabetes"},{"key":"1329_CR44","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2015. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about. Accessed Sept 25, 2019."},{"key":"1329_CR45","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.juro.2009.01.034","volume":"181","author":"MD Sorensen","year":"2009","unstructured":"Sorensen MD, Krieger JN, Rivara FP, et al. Fournier's gangrene: population based epidemiology and outcomes. J Urol. 2009;181:2120\u20136.","journal-title":"J Urol"},{"key":"1329_CR46","unstructured":"AstraZeneca. Forxiga (dapagliflozin) US prescribing information. 2018. https:\/\/www.azpicentral.com\/farxiga.pdf#page=1. Accessed Nov 18, 2018."},{"key":"1329_CR47","unstructured":"US Food and Drug Administration. Briefing document: NDA 202293 dapagliflozin oral tablets, 5 and 10\u00a0mg. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/202293Orig1s000RiskR.pdf. Accessed Nov 18, 2018."},{"key":"1329_CR48","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1007\/s00125-017-4430-0","volume":"60","author":"S Kohler","year":"2017","unstructured":"Kohler S, Lee J, George JT, et al. Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia. 2017;60:2534\u20135.","journal-title":"Diabetologia"},{"key":"1329_CR49","unstructured":"US Food and Drug Administration. Canagliflozin (Invokana, Invokamet): Drug safety communication\u2014increased risk of leg and foot amputations. 2017. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm557507.htm. Accessed Nov 18, 2018."},{"key":"1329_CR50","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01329-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01329-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01329-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T14:16:59Z","timestamp":1650205019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01329-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01329-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}